The therapeutic gap - compliance with medication and guidelines

被引:26
作者
Feely, J [1 ]
机构
[1] St James Hosp, Trinity Ctr Hlth Sci, Dept Therapeut, Dublin 8, Ireland
[2] St James Hosp, Trinity Ctr Hlth Sci, Lipid Clin, Dublin 8, Ireland
关键词
therapeutic gap : EUROASPIRE survey; PREVENIR survey; PREVESE study; myocardial infarction; prescribing behaviour influences : patient compliance;
D O I
10.1016/S0021-9150(99)00253-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Hospitals, clinics and cardiologists have a significant impact on prescribing in general practice. Physicians in primary care rank hospital recommendations as one of the most important sources of information on new drugs. However, recent surveys of coronary heart disease (CHD) prevention paint a depressing picture about the current evidence-based management of risk factors, such as hypercholesterolaemia and hypertension, in both secondary- and primary-care settings. European guidelines have identified secondary prevention as the top priority in patients with established CHD and lowered cholesterol thresholds in light of evidence, not only from the 4S study, but also from the CARE and LIPID studies, which highlighted the risks posed by even normal or moderately elevated cholesterol levels. There is a clear need for those involved in duality assurance in hospital care to take ownership of such guidelines. Cardiologists can play a key role - they do not face the problem alone, but evidence suggests that they can have a significant positive impact on the management of CHD risk factors in primary care. (C) 1999 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:S31 / S37
页数:7
相关论文
共 34 条
[1]  
Allery LA, 1997, BMJ-BRIT MED J, V314, P870
[2]   DISCONTINUATION OF ANTIHYPERLIPIDEMIC DRUGS - DO RATES REPORTED IN CLINICAL-TRIALS REFLECT RATES IN PRIMARY-CARE SETTINGS [J].
ANDRADE, SE ;
WALKER, AM ;
GOTTLIEB, LK ;
HOLLENBERG, NK ;
TESTA, MA ;
SAPERIA, GM ;
PLATT, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (17) :1125-1131
[3]  
[Anonymous], 1997, Eur Heart J, V18, P1569
[4]  
Armstrong D, 1996, BRIT MED J, V312, P949
[5]  
Baxter C, 1998, BMJ-BRIT MED J, V317, P1134
[6]   A British cardiac society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action on Secondary Prevention through Intervention to Reduce Events) - Principal results [J].
Bowker, TJ ;
Clayton, TC ;
Ingham, J ;
McLennan, NR ;
Hobson, HL ;
Pyke, SDM ;
Schofield, B ;
Wood, DA .
HEART, 1996, 75 (04) :334-342
[7]  
CANNON PJ, 1988, LANCET, V1, P979
[8]   The west of Scotland coronary prevention study: economic benefit analysis of primary prevention with pravastatin [J].
Caro, J ;
Klittich, W ;
McGuire, A ;
Ford, J ;
Norrie, J ;
Pettitt, D ;
McMurray, J ;
Shepherd, J .
BRITISH MEDICAL JOURNAL, 1997, 315 (7122) :1577-1582
[9]   Do "America's best hospitals" perform better for acute myocardial infarction? [J].
Chen, J ;
Radford, MJ ;
Wang, Y ;
Marciniak, TA ;
Krumholz, HM .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (04) :286-292
[10]  
DENHARTOQ FR, 1998, EUR HEART J SUPPL, V19, P2802